Saratov JOURNAL of Medical and Scientific Research
Home

Pentraxin-3: Possibilities and perspectives for using the biomarker in patients with previous COVID-19

Year: 2024, volume 20 Issue: №1 Pages: 22-28
Heading: Internal Diseases Article type: Original article
Authors: Kanaeva T.V., Karoli N.A.
Organization: Saratov State Medical University
Summary:

Objective: to determine the potential prognostic value of serum biomarkers in relation to the development of adverse cardiovascular events in patients who have undergone COVID-19. Material and methods. The prospective study involved 114 patients hospitalized with confirmed COVID-19. In addition to standard examinations, blood samples were taken from patients on the day of hospitalization to determine the level of serum cardiovascular biomarkers, including pentaxin-3 (РТХЗ). The patients were monitored for 366 [365; 380] days after discharge from the COVID hospital with registration of major adverse cardiovascular events (MACE) developed in patients. Results. During follow-up, MACE was noted in 19 patients (16.7%), including 2 deaths (1.8%) from cardiovascular causes. The incidence of MACE was higher in patients with higher concentrations of РТХЗ (odds ratio — OR 1.28, 95% confidence interval — Cl 1.13-1.45; p<0,001), interleukin 6 (OR 1.01, 95% Cl 1.0-1.02; p=0.048), D-dimer (OR 2.05, 95% Cl 1.16-3.6; p=0.019), lactate dehydrogenase (OR 1.08, 95% Cl 1.03-1.13; p<0.001), creatine phosphokinase-MB (OR 1.19, 95% Cl 1.02-1.39; p=0.001). The concentration of PTX3>3.1 ng/ml predicted the development of MACE with a sensitivity of 94.0% and a specificity of 82.1% (AUC 0.885; p<0.001). Conclusion. Serum biomarkers, in particular РТХЗ, may be used to predict the development of MACE in the long-term follow-up of patients who have undergone COVID-19.

Keywords: pentraxin-3 (РТХЗ), major adverse cardiovascular events, COVID-19, cardiovascular diseases

Bibliography:
1. Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020; 8 (6): 544-6. DOI: 10.1016/S2213-2600(20)30226-5
2. Miyamoto T, Qureshi RA, Heimburger O, et al. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol. 2011; 6 (12): 2785-91. DOI: 10.2215/ С JN. 02320311
3. AgrawalA, Singh PP, Bottazzi B, etal. Pattern recognition by pentraxins. Adv Exp Med Biol. 2009; 653: 98-116. DOI: 10.1007/978-1 -4419-0901 -5_7
4. SchallerT, Hirschbuhl K, Burkhardt K, et al. Postmortem examination of patients with COVID-19. JAMA. 2020; 323 (24): 2518-20. DOI: 10.1001/jama.2020.8907
5. Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020; 22 (5): 911-5. DOI: 10.1002/ejhf.1828
6. Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846-8. DOI: 10.1007/s00134-020-05991-x
7. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5 (7): 802-10. DOI: 10.1001/ jamacardio. 2020.0950
8. Kaufmann CC, Ahmed A, Burger AL, et al. Biomarkers associated with cardiovascular disease in COVID-19. Cells. 2022; 11 (6): 922. DOI: 10.3390/cells11060922
9. Bottazzi B, Garlanda C, Teixeira MM. Editorial: The role of pentraxins: From inflammation, tissue repair and immunity to biomarkers. Front Immunol. 2019; 10: 2817. DOI: 10.3389/ fimmu. 2019.02817
10. Brunetta E, Folci M, Bottazzi B, et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2021; 22 (1): 19-24. DOI: 10.1038/S41590-020-00832-x
11. Schirinzi A, Pesce F, Laterza R, et al. Pentraxin 3: Potential prognostic role in SARS-CoV-2 patients admitted to the emergency department. J Infect. 2021; 82 (4): 84-123. DOI: 10.1016/j.jinf.2020.10.027
12. Avdeev SN, Adamyan LV, Alekseeva El, et al. Interim guidelines on "Prevention, diagnosis and treatment of emerging coronavirus infection (COVID-19)". Version 16 (18.08.2022). Moscow, 2022; 249 p.
13. Jenny NS, Blumenthal RS, Kronmal RA, et al. Associations of pentraxin 3 with cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2014; 12 (6): 999-1005. DOI: 10.1111/jth.12557
14. Latini R, Gullestad L, Masson S, et al. Pentraxin-3 in chronic heart failure: The CORONA and GISSI-HF trials. Eur J Heart Fail. 2012; 14 (9): 992-9. DOI: 10.1093/eurjhf/hfs092
15. Gareeva DF, Khamitova AF, Lakman IA, et al. Prognostic significance of a combination of novel biomarkers in the long-term stratification of adverse outcomes in patients with ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020; 25 (12): 3948. DOI:10.15829/1560-4071-2020-3948
16. Zagidullin N, Motloch LJ, Gareeva D, et al. Combining novel biomarkers for risk stratification of two-year cardiovascular mortality in patients with ST-elevation myocardial infarction. J Clin Med. 2020; 9 (2): 550. DOI: 10.3390/jcm9020550
17. Linschoten M, Asselbergs FW. CAPACITY-COVID: A European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart J. 2020; 41 (19): 1795-6. DOI: 10.1093/eurheartj/ehaa280
18. Tong M, Xiong Y, Zhu C, et al. Elevated serum pentraxin-3 levels is positively correlated to disease severity and coagulopathy in COVID-19 patients. Mediterr J Hematol Infect Dis. 2020; 13 (1): e2021015. DOI: 10.4084/mjhid. 2021.015
19. Gene AB, Yaylaci S, Dheir H, et al. The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia. Turk J Med Sci. 2021; 51 (2): 448-53. DOI: 10.3906/sag-2011-32
20. Protti A, Meessen J, Bottazzi B, et al. Circulating pentraxin 3 in severe COVID-19 or other pulmonary sepsis. Eur J Clin Invest. 2021; 51 (5):e13530. DOI: 10.1111/eci.13530

AttachmentSize
2024_01_022-028.pdf423.83 KB
All articles of the authors: Karoli N.A., Kanaeva T.V.

No votes yet